Imugene Yönetim

Yönetim kriter kontrolleri 1/4

Imugene CEO'su Leslie Chong, Nov2016 tarihinde atandı, in görev süresi 6.67 yıldır. in toplam yıllık tazminatı A$ 2.50M olup, şirket hissesi ve opsiyonları dahil olmak üzere 31.2% maaş ve 68.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.07% ine doğrudan sahiptir ve bu hisseler A$ 2.96M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.7 yıl ve 6.1 yıldır.

Anahtar bilgiler

Leslie Chong

İcra Kurulu Başkanı

AU$2.5m

Toplam tazminat

CEO maaş yüzdesi31.2%
CEO görev süresi8yrs
CEO sahipliği1.1%
Yönetim ortalama görev süresi1.7yrs
Yönetim Kurulu ortalama görev süresi6.1yrs

Son yönetim güncellemeleri

Recent updates

Is Imugene (ASX:IMU) In A Good Position To Invest In Growth?

Aug 29
Is Imugene (ASX:IMU) In A Good Position To Invest In Growth?

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Apr 12
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Sep 19
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

May 30
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Jan 30
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11
Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17
A Look At Imugene's (ASX:IMU) CEO Remuneration

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24
Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

CEO Tazminat Analizi

Leslie Chong'un ücretlendirmesi Imugene'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024AU$2mAU$780k

-AU$150m

Mar 31 2024n/an/a

-AU$119m

Dec 31 2023n/an/a

-AU$89m

Sep 30 2023n/an/a

-AU$64m

Jun 30 2023AU$2mAU$750k

-AU$38m

Mar 31 2023n/an/a

-AU$39m

Dec 31 2022n/an/a

-AU$40m

Sep 30 2022n/an/a

-AU$39m

Jun 30 2022AU$1mAU$600k

-AU$38m

Mar 31 2022n/an/a

-AU$33m

Dec 31 2021n/an/a

-AU$27m

Sep 30 2021n/an/a

-AU$23m

Jun 30 2021AU$789kAU$408k

-AU$18m

Mar 31 2021n/an/a

-AU$15m

Dec 31 2020n/an/a

-AU$12m

Sep 30 2020n/an/a

-AU$11m

Jun 30 2020AU$733kAU$375k

-AU$11m

Mar 31 2020n/an/a

-AU$10m

Dec 31 2019n/an/a

-AU$9m

Sep 30 2019n/an/a

-AU$8m

Jun 30 2019AU$777kAU$350k

-AU$8m

Mar 31 2019n/an/a

-AU$7m

Dec 31 2018n/an/a

-AU$6m

Sep 30 2018n/an/a

-AU$5m

Jun 30 2018AU$403kAU$300k

-AU$4m

Tazminat ve Piyasa: Leslie 'nin toplam tazminatı ($USD 1.63M ), Australian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 688.70K ).

Tazminat ve Kazançlar: Leslie şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Leslie Chong

8yrs

Görev süresi

AU$2,497,743

Tazminat

Ms. Leslie Chong served as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020 until July 2023. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Paul Hopper
Executive Chairman12.1yrsAU$491.35k5.5%
A$ 15.1m
Leslie Chong
CEO, MD & Executive Director8yrsAU$2.50m1.07%
A$ 3.0m
Michael Tonroe
CFO & Company Secretary2.2yrsAU$810.31kVeri yok
Bradley Glover
Chief Operating Officer1.3yrsAU$1.75mVeri yok
Joseph Woodard
Chief Medical Officer1.2yrsAU$1.39mVeri yok
Ursula McCurry
Chief Clinical Operations Officer2.8yrsVeri yokVeri yok
John Byon
Senior Vice President of Clinical Development1.2yrsVeri yokVeri yok

1.7yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: IMU 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Paul Hopper
Executive Chairman12.1yrsAU$491.35k5.5%
A$ 15.1m
Leslie Chong
CEO, MD & Executive Director6.7yrsAU$2.50m1.07%
A$ 3.0m
Kimberlee Drapkin
Non-Executive Director1.4yrsAU$92.40k0.0016%
A$ 4.4k
Yuman Fong
Chair of Oncolytic Virotherapy Scientific Advisory Board5yrsVeri yok0.30%
A$ 828.0k
Neil Segal
Member of Scientific Advisory Board10.6yrsVeri yokVeri yok
Josep Tabernero Caturla
Member of Scientific Advisory Board6.1yrsVeri yokVeri yok
Yelena Janjigian
Scientific Advisory Board Member8.6yrsVeri yokVeri yok
Lesley Russell
Independent Non-Executive Director5.6yrsAU$114.50k0.27%
A$ 748.8k
Peter Schmid
Member of Scientific Advisory Board6.9yrsVeri yokVeri yok
Tanios Bekaii-Saab
Member of Scientific Advisory Board6.2yrsVeri yokVeri yok
Pravin T. Kaumaya
Member of Scientific Advisory Board6.1yrsVeri yokVeri yok
Prasad Adusumilli
Member of Scientific Advisory Board5yrsVeri yokVeri yok

6.1yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IMU 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.1 yıldır).